Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)23.00
  • Today's Change-0.20 / -0.86%
  • Shares traded29.00
  • 1 Year change-10.30%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Genus PLC's revenues fell -3.03% from 689.70m to 668.80m. 33.30m to 7.90m, a -76.28% decrease.
Gross margin--
Net profit margin0.36%
Operating margin0.96%
Return on assets0.24%
Return on equity1.41%
Return on investment0.27%
More ▼

Cash flow in GBPView more

In 2024, Genus PLC increased its cash reserves by 17.08%, or 6.20m. The company earned 29.80m from its operations for a Cash Flow Margin of 4.46%. In addition the company used 19.30m on investing activities and also paid 2.80m in financing cash flows.
Cash flow per share0.749
Price/Cash flow per share24.86
Book value per share8.30
Tangible book value per share5.64
More ▼

Balance sheet in GBPView more

Genus PLC has a Debt to Total Capital ratio of 34.87%, a lower figure than the previous year's 37.90%.
Current ratio1.80
Quick ratio1.21
Total debt/total equity0.5312
Total debt/total capital0.3487
More ▼

Growth rates in GBP

SmartText is unavailable
Div yield(5 year avg)1.06%
Div growth rate (5 year)2.93%
Payout ratio (TTM)265.82%
EPS growth(5 years)-0.01
EPS (TTM) vs
TTM 1 year ago
-76.49
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.